Studies of expression quantitative trait loci (eQTLs) offer insight into the molecular mechanisms of loci that were found to be associated with complex diseases and the mechanisms can be classified into cis-and trans-acting regulation. At present, high-throughput RNA sequencing (RNA-seq) is rapidly replacing expression microarrays to assess gene expression abundance.
INTRODUCTION
Expression quantitative trait loci (eQTLs) mapping searches across the genome for variants that regulate expression levels of messenger RNAs. Studies of eQTLs can not only discover the genetic basis underlying the variation in gene expression but also decipher molecular mechanisms of loci that were found to be associated with complex diseases by genome-wide association studies (GWAS) (Cookson et al. 2009 ). At present, high-throughput RNA sequencing (RNA-seq) is rapidly replacing expression microarrays to assess gene expression abundance.
To date, The Cancer Genome Atlas (TCGA) project has collected RNA-seq data on >5,000 samples over 17 cancers. These data hold the potential to characterize the functional roles of GWAS hits , which can later be translated into clinical benefits such as cancer treatments. However, traditional methods for eQTL mapping were developed for microarray expression data (Kendziorski and Wang 2006) and may no longer be appropriate for RNA-seq data.
Compared with microarrays that only measure the total expression of each gene, one important feature of RNA-seq is its ability to measure allele-specific expression (ASE). In a diploid individual, each chromosome consists of a paternal copy and a maternal copy, and each gene comprises a paternal allele and a maternal allele. The expression of each allele of a gene is referred to as its ASE, which has been used to distinguish between cis-and transeQTLs. By definition, a cis-eQTL is located on the same chromosome as the target gene (e.g., transcriptional factor binding site of the gene) and the DNA variation on the paternal (or maternal) chromosome only influences the transcription process of the paternal (or maternal) gene allele. By contrast, a trans-eQTL can be located anywhere in the genome and influences the transcription of the target gene by modifying the abundance or activity of a protein that regulates the gene; this regulation does not discriminate between the two alleles. Therefore, a cis-regulation typically leads to differential ASE between the two alleles of an individual whereas a trans-regulation generally results in the same amount of expression change. Such a pattern of ASE can be used to distinguish cis-eQTLs from trans-eQTLs. More importantly, the difference in ASE offers another layer of information on top of the total gene expression to enhance cis-eQTL mapping.
With RNA-seq data, the ASE can be measured by sequence reads that are unambiguously mapped to each of the two gene alleles. For an individual, the usable reads must overlap with at least one exonic single nucleotide polymorphism (SNP) at which the individual carries a heterozygous genotype. In Figure 1 (a), we illustrate the quantification of ASE for a hypothetical gene with two exons and two exonic SNPs. In individual (i), four and two reads harbor alleles A and T, respectively, at the first exonic SNP, and four and two reads harbor alleles A and G, respectively, at the second exonic SNP. Thus, the ASE is estimated to be eight and four for gene alleles containing the haplotypes A-A and T-G, respectively. In individual (ii), only the eight reads overlapping with the first SNP can be counted into the ASE measure. In individual (iii), no read can be counted into ASE.
Using the ASE, cis-eQTL mapping assesses whether one allele of a (biallelic) SNP is associated with a higher or lower ASE than the other allele. We use Figure 1 (a-b) to illustrate this process. In individual (i), after the haplotypes are inferred as C-A-A and T-T-G and the ASE is quantified as above, alleles C and T of the candidate cis-eQTL are linked with the ASE measurements of eight and four, respectively ( Figure 1[a] ). Because allele C is associated with a higher ASE than allele T, this SNP is likely a cis-eQTL ( Figure 1[b] ). Note that only individuals heterozygous at the candidate eQTL provide information for cis-eQTL mapping. The ASE measured as above is only comparable within individuals, with one ASE measurement serving as the control for the other, but not comparable across individuals.
Evidently, the phase information is essential to link the ASE with the alleles of the candidate cis-eQTL. Many algorithms (Stephens et al. 2001; Browning and Browning 2009; Li et al. 2010; Delaneau et al. 2012) have been developed to infer the haplotype phase from the genotypes of unrelated individuals. It is often reasonable to assume that the inferred phase is accurate within the gene body, because genes are relatively short (Flicek et al. 2011) , and RNA-seq reads that span over two or more SNPs provide direct information on the phase.
However, the phasing accuracy tends to deteriorate when the haplotypes extend to the candidate eQTL, which is often located in an inter-genic region and can be a few hundred kilobases (kb) away from the gene. Incorrectly linking the SNP alleles with the ASE will greatly compromise the power of cis-eQTL mapping.
Besides the ASE, the total gene expression, which is measured by the total read count (TReC) (i.e., the total number of reads mapped to the gene), also provides information for cis-eQTL mapping. As shown in Figure 1 (c), the individual with genotype CC has the highest TReC followed by the individual with CT and then TT, and such a pattern is consistent with the aforementioned observation that allele C is associated with a higher ASE than allele T.
Note that the quantification of TReC is not confined to reads that overlap with SNPs showing heterozygous genotypes. Thus, the TReC is generally much greater than the sum of the two ASE measurements and can be compared across individuals.
Traditional methods for eQTL mapping, which were originally developed for microarray expression data, have been applied to the RNA-seq TReC data after normalization (Pickrell et al. 2010) . These methods do not exploit the ASE information, ignore the digital nature of the read count data, and cannot distinguish between cis-and trans-eQTLs. To incorporate both the ASE and TReC data available from RNA-seq for cis-eQTL mapping, Sun (2012) proposed a two-stage approach that first phases the candidate eQTL against the target gene and then treats the inferred phase as observed in assessing the cis-effect. This approach, pertaining to single imputation in the missing data literature, has two limitations. First, the phasing process disregards the gene expression, which is potentially informative about the missing phase, especially for a true cis-eQTL. Second, the downstream association analysis ignores the uncertainties in the inferred phase. Consequently, the two-stage approach tends to attenuate the estimated cis-effect and reduce the power for detecting a cis-eQTL. A further challenge, which has not been addressed in previous work, remains to develop computationally efficient methods to evaluate the significance of eQTL findings when multiple, correlated SNPs are tested for each gene.
In this article, we propose a maximum-likelihood approach for cis-eQTL mapping that incorporates both the ASE and TReC data. Unlike Sun (2012) , our approach integrates the phasing of the candidate eQTL and the association analysis into a single stage. Thus, our maximum-likelihood estimators (MLEs) for cis-effects are unbiased and statistically efficient in the sense that the corresponding test of association is the most powerful among all valid tests based on the same data and same assumptions. Within the maximum-likelihood framework,
we develop a five-step pipeline ( Figure 2 ) for performing the comprehensive analysis of all local eQTLs for all genes in the genome. Here, we restrict the candidate eQTLs to the local SNPs and focusing on the SNP with the minimum p-value (referred to as the minimum-p SNP) for each gene, (2) assessing the significance of each minimum-p SNP, (3) detecting eQTLs among genome-wide minimum-p SNPs by controlling for false discovery rate (FDR), (4) distinguishing between cis-and trans-acting regulations at detected eQTLs, and (5) estimating the effect sizes at detected eQTLs. We implement the proposed methods, including an ultra-fast permutation process for step (2), in a computationally efficient program. We show in realistic simulation studies that the proposed approach is more powerful than the two-stage approach and the use of the TReC data alone. We further demonstrate the usefulness of the new methodology and software program in an application to the breast cancer data from TCGA.
METHODS

ASE Model
Suppose that each SNP is biallelic with allele values 0 and 1. Thus, each haplotype is a unique sequence of 0s and 1s on one copy of a chromosome. We denote the K possible haplotypes at the M exonic SNPs within a gene by h 1 , . . . , h K , and denote the ordered diplotype consisting of haplotypes h m and h n by H = ( h m , h n ), where m, n = 1, . . . , K. For the reasons mentioned earlier, we assume that H = ( h m , h n ) is known. For a candidate eQTL, let G be the genotype, which is the number of allele 1, and let G 1 be the phase, which is the number of allele 1 on the same chromosomal copy as h m . The candidate eQTL can be outside or inside the gene body. We focus on the former case, under which G 1 is unknown for individuals who are heterozygous at the candidate eQTL; the latter case is trivial as G 1 would be known. We use H to infer G 1 by exploiting the linkage disequilibrium (LD) between the exonic SNPs and the candidate eQTL. To this end, we consider the joint distribution of the M = M + 1 SNPs.
Let H = (h k , h l ) be the ordered diplotype at the M SNPs, where k, l = 1, . . . , K indexing the K possible haplotypes. Write π k = Pr(h = h k ) and π = (π 1 , . . . , π K ) , where ν denotes the transpose of the vector ν. Under Hardy-Weinberg equilibrium (HWE), the frequency of H = (h k , h l ) is π k π l , denoted by P π {H = (h k , h l )}. Both H and G 1 are unknown. Once H is inferred as (h k , h l ), G 1 is simply the value of h k in the position of the candidate eQTL.
The ASE data are represented by the number of allele-specific reads mapped to h m and the sum of the two allele-specific read counts, denoted by R 1 and R, respectively. Note that R 1 pertains to the same chromosomal copy as G 1 . Because R 1 is not comparable across individuals, we model the conditional probability of R 1 = r 1 given R = r by a beta-binomial distribution with a success rate p k,l and a dispersion parameter ψ, P β A ,ψ (r 1 |r, (h k , h l )) = r r 1 r 1 −1 j=0 (p k,l + jψ) r−r 1 −1 j=0
(1 − p k,l + jψ) 
with β A characterizing the effect of G 1 on R 1 . The beta-binomial distribution is an extension of the binomial distribution Bin(r, p k,l ) to allow for over-dispersion. When there is no allelespecific read, i.e., r = 0, we set P β A ,ψ (r 1 |r, (h k , h l )) = 1. Note that the covariates (e.g., intercept term, demographical or environmental factors) are ignored, because the comparison is between R 1 and R − R 1 within an individual so that any covariate effect is canceled out.
Because H (or equivalently, G 1 ) may be missing, the likelihood based on the observed data (R 1i , R i , G i , H i ) (i = 1, . . . , N ) involves a summation:
where H i ∼ (G i , H i ) denotes the set of H i s that are compatible with G i and H i . If G i = 1, such a set consists of two elements, {(1, h m ), (0, h n )} and {(0, h m ), (1, h n )}. If G i = 0 or 2, then H i is uniquely determined. As noted earlier, only individuals with G i = 1 and R i > 0 provide information about the effect size β A . However, all individuals with R i > 0 are used for estimating the over-dispersion parameter ψ, and all, including those with R i = 0, are used for estimating the haplotype frequencies in π. We refer to (2) as the ASE model. The two-stage approach (Sun 2012) can be viewed as a special case of (2) in that the set H i ∼ (G i , H i ) only contains the inferred value and P π (H i ) factors out.
TReC and TReCASE Models
Denote the TReC of the gene by T . We adopt the TReC model of Sun (2012) for assessing the effect of genotype G on T . We reformulate his TReC model in this section to conform to the notation in this article. Let X be a set of p covariates including the unit component.
The probability of T = t given the genotype G = g and the covariates X = x is formulated through a negative-binomial distribution with mean µ x,g and a dispersion parameter φ:
where Γ(.) is the Gamma function. The negative-binomial distribution is a generalization of the Poisson distribution to allow for over-dispersion. The covariate-adjusted effect of G on T , characterized by β T , is formulated through the regression model
where
The form of Z(g, β T ) reflects the additive genetic effect. To see this, we first write log(µ x,0 ) = γ x and log(µ x,2 ) = γ x+β T , from which we obtain β T = log(µ x,2 /µ x,0 ). Then, it follows from the additive effect that log(µ x,1 ) = log(µ x,0 +µ x,2 )−log 2 = log(µ x,0 )+log(1+µ x,2 /µ x,0 )−log 2, which satisfies (3) and (4) after replacing µ x,2 /µ x,0 by exp(β T ). The additive model is the most commonly used in eQTL studies. Indeed, a cis-effect is additive by definition. Finally, the likelihood based on the data (
When an eQTL cis-regulates the gene expression, we have β A = β T . To show this, we introduce υ 1 and υ 0 as the mean ASE corresponding to alleles 1 and 0, respectively, of the candidate eQTL at the baseline of X. For individuals with G = 1 and G 1 = 1, we have p k,l = υ 1 /(υ 1 + υ 0 ) and then β A = log{p k,l /(1 − p k,l )} = log(υ 1 /υ 0 ); for those with G = 1 and
On the other hand, we have β T = log(µ x,2 /µ x,0 ) = log{2υ 1 /(2υ 0 )}, where the second equation follows from the additivity assumption. Therefore, we obtain β A = β T and denote them by a common effect size β. To combine the ASE and TReC data for inference on β, we employ the joint likelihood
We refer to (6) as the TReCASE model. Again, the two-stage approach using the combined data is a special case of (6). A trans-eQTL implies that β T = 0 and β A = 0. In that case, the TReCASE model is not appropriate because the ASE data provide no information for the association but simply introduce noise. The TReC model alone should be used for trans-eQTL mapping.
A Measure of Phasing Accuracy
In theory, the ASE and TReCASE models allow the use of all exonic SNPs in the target gene to predict the phase of a candidate eQTL. In practice, there may be a significant number of exonic SNPs, which would form a large pool of haplotypes and cause some haplotype frequencies too small to be estimated. To balance between the predictive power and the numerical stability, we select a small number of exonic SNPs that provide the best prediction.
In this article, we set M to four following much of the literature (de Bakker et al. 2005; Nicolae 2006; Lin et al. 2008) . To guide the selection of exonic SNPs, we develop a measure, called Rsq, to quantify the amount of information in a given set of exonic SNPs for predicting the phase; see Appendix A for details. Rsq takes values between 0 and 1, with 0 and 1 indicating that the set of exonic SNPs provide none and complete information, respectively. For a candidate eQTL, we evaluate all sets of M exonic SNPs and select the one with the largest value of Rsq.
Testing A Gene-SNP Pair
The genome-wide scan of gene-SNP pairs involves tens of thousands of genes and hundreds 
Assessing the Significance of the Minimum-p SNP
Due to multiple testing, the score-based p-value at the minimum-p SNP is no longer indicative of the significance level. In addition, such p-values are not comparable across genes, as different genes have different numbers of local SNPs. To evaluate the significance of the minimum-p SNPs, we propose a permutation process that is tailored to the score statistics and features ultra-fast computation. We permute the dataset by fixing (T, X, R 1 , R), shuffling G and H as a whole among the individuals, and then randomly switching h m and h n in H = ( h m , h n ) of an individual. Because the nuisance parameters have been estimated without reference to the genetic association in the original dataset, they do not need to be re-estimated in the permuted datasets in which the association is altered. Thus, the analysis of the permuted datasets only involves simple re-evaluation of the cross-products between (T, X, R 1 , R) and (G, H) in the score statistics. This is fundamentally different from the traditional permutation process employed by Sun (2012) , which repeats exactly the same (iterative) analysis for the permuted datasets as for the original one. We generate B permuted datasets (e.g., B = 5, 000) and calculate the permutation p-value by taking the proportion of permuted datasets that generate smaller minimum p-values than the observed one.
Detecting eQTLs Among Genome-Wide Minimum-p SNPs by FDR Control
We adopt the method of Storey and Tibshirani (Storey and Tibshirani 2003) for estimating FDR. Specifically, for any p-value cutoff p c , the FDR is estimated by p 0 p c N total /N eQTL , where N total is the total number of minimum-p SNPs, N eQTL is the number of those with permutation p-values ≤ p c , and p 0 is the expected proportion of minimum-p SNPs having null effects and is calculated as two times the proportion of minimum-p SNPs with permutation p-values ≥ 0.5.
We explore over a fine grid of cutoffs and select the one that generates the desired FDR, e.g., 5% or 10%. Then, the minimum-p SNPs whose permutation p-values lower than the final cutoff are declared as eQTLs. When the procedure is applied to the minimum-p SNPs from the TReC and TReCASE models separately with the same FDR, the combined minimum-p SNPs are also controlled for that FDR level.
Distinguishing Between cis and trans Mechanisms at eQLTs
After an eQTL is identified, the mechanism can be determined by the following cis-trans test. Let β A = β and β T = β + α. The hypotheses are written as
We employ a score statistic (derived in Appendix B), which is computationally more efficient and numerically more stable than the likelihood-ratio statistic adopted by Sun (2012) .
Up to this point, the TReC and TReCASE models work independently and may identify different eQTLs for the same gene. The cis-trans tests at the two eQTLs may yield the same or different conclusions. If both eQTLs are determined to be cis, we only retain the one identified by TReCASE, in consistent with our focus on only one cis-eQTL for a gene. Likewise, if both eQTLs are established to be trans, we only retain the one identified by TReC. If one eQTL is determined to be cis and another trans, we keep both for future validation, as a gene can be subject to different regulations.
Estimating Effect Sizes of eQTLs
For a detected eQTL, the effect sizes in the ASE, TReC and TReCASE models can be estimated by maximizing the likelihood functions (2), (5) and (6), respectively. Note that, although the ASE model on its own is not used in the steps described in Sections 2.4-2.7, its effect size offers a unique insight into the ASE data alone. Because of missing phases, the maximization of (2) and (6) can be carried out by the expectation-maximization (EM) algorithms described in Appendix B. The maximization of (5) can be achieved by a standard Newton-Raphson algorithm. By the classical likelihood theory, the MLEs of the effect sizes are consistent, asymptotically normal and asymptotically efficient. Their variances can be estimated by the Louis formula (Louis 1982) , as provided in Appendix B.
SIMULATION STUDIES
We carried out extensive simulation studies to evaluate the performance of the proposed and two-stage methods in realistic settings. To make a fair comparison between the two approaches, we considered a phasing method for the two-stage approach that uses the same amount of information as the proposed approach. Specifically, the method selects the M exonic SNPs that yield the maximum Rsq for a candidate eQTL, and infers the diplotype H i for the ith individual by the one that corresponds to the largest
where π is obtained by maximizing (7) in Appendix A. In Supplementary Method S1, we proved that treating the inferred phase as observed in the ASE model yields a valid test of the hypothesis H 0 : β A = 0, provided that H is independent of R 1 and R. We refer to the proposed maximum-likelihood approach and the two-stage (imputation) approach as MLE and IMP, respectively. As a benchmark, the approach using the true phase is also included and referred to as TRUE. We set the nominal significance level to be 0.05, which is realistic because the commonly used FDR values of 5% and 10% correspond to the p-value cutoff of 0.023 and 0.062 in our analysis of TCGA breast cancer data.
The first study was focused on the effect size estimation and association testing at a cis-eQTL, when the four exonic SNPs are fixed. We generated genotype data for various sets of five SNPs according to the LD patterns observed in the TCGA breast cancer data (Supplementary Table S1 ). For each SNP set, we chose one SNP to be the cis-eQTL, leaving the other four to be exonic SNPs. The Rsq values of the exonic SNPs for phasing the cis-eQTL range from 0.56 to 0.93, which represent a wide spectrum of phasing accuracy according to the empirical distribution of Rsq values ( Figure 6 ). Given the cis-eQTL, the expression data were generated from the association models, whose nuisance parameters were set at typical values observed in the TCGA data. Specifically, the TReC T was simulated from a negative-binomial distribution with µ X,G = 900 × exp{0.1X + Z(G, β T )} and φ = 0.2, where X was a normal random variable with mean zero and variance one. Then, R was obtained as the integer part of 0.034 × T , where 0.034 was the average proportion of TReC that were allele-specific, and R 1 was simulated from a beta-binomial distribution with p k,l in (1) and ψ = 0.05. We generated 79 subjects (unless otherwise specified) for each dataset, which was the sample size of the Table S2 ). As predicted by our theory, IMP yielded proper type I error under the null hypothesis. In the presence of association, however, the estimates of β produced by IMP are seriously biased towards zero, especially when Rsq is low.
Consequently, IMP is uniformly less powerful than MLE; the power difference can be seen more clearly in Figure 3 . As Rsq approaches 1, both MLE and IMP are nearly as powerful as TRUE. We also applied the ASE model to the same data, whose results show similar patterns (Supplementary Table S3 and Supplementary Figure S1 ).
The second simulation study was designed to assess the validity and power of using the minimum-p SNP and the proposed permutation process. Unlike the first study, we generated with the gene expression, and in the MLE and IMP methods, at most four exonic SNPs were selected for informing the phase of a candidate eQTL. Figure S2) , confirming the validity of the permutation process even for the small sample size. In the present of cis-effects, MLE is uniformly more powerful than IMP and TReC (Figure 4) , and is as powerful as TRUE for gene MAP7D1 whose average value of Rsq at the minimum-p SNPs is as high as 0.80 (Table 2) . When Rsq decreases to 0.4 and below, MLE tends to have lower power than TReC (Supplementary Figure S3) . This is not surprising because, in such cases, the uncertainties about the phase overweigh the information contained in the ASE data and incorporating the ASE data even hurt the power from using the TReC data alone.
In the third simulation study, we investigated the MLE and IMP methods in distinguishing between cis-and trans-eQTLs, using the five-SNP settings in the first study. To examine the type I error of the cis-trans test, we considered various cis-effect sizes. As shown in Figure   5 , IMP tends to generate inflated type I error (i.e., declaring excessive eQTLs to be trans), especially when Rsq is low and the cis-effect sizes are large. This is because IMP generally yields biased estimates for β A , thereby creating a difference between β A and β T . By contrast, MLE produced reasonable type I error rates in all cases, although a slight inflation can be observed due to the small sample size of 79. We then assessed the power of the cis-trans test by simulating trans-effects, which implies that β A = 0. As shown in Supplementary Figure   S4 , IMP has the same power as TRUE, because the phasing does not matter when β A = 0;
note that IMP has accurate control of type I error in this particular case. MLE lost power relative to IMP and TRUE due to its enlarged variance to account for phasing uncertainty, but the power loss is very modest. We also assessed the power of the cis-trans test conditional on β A = 0, whose alternative hypothesis (β A = 0 and β A = β T ), although corresponding to neither cis-nor trans-effect, may exist in reality through other mechanisms. Supplementary Figure S4 displays the power curves when β A was set to 0.5. Now that the phasing does matter, IMP has a shifted power curve compared to MLE and TRUE; the minimum power is not attained at the null of β T = β A = 0.5 but somewhere below 0.5.
APPLICATION TO TCGA DATA
We performed an analysis of local eQTLs (within 200 kb of a gene) for the genome-wide expression in 79 breast cancer (OMIM114480) patients from TCGA, using the RNA-seq data autosomal genes were derived from the RNA-seq data by the R packages asSeq (Sun 2012) and isoform (http://www.bios.unc.edu/∼weisun/software/isoform.htm). We note that using the imputation-augmented SNP set greatly increased the number of reads that can be counted into the ASE measurements. Supplementary Method S2 has more details on the processing of the RNA-seq data.
We restricted the candidate eQTLs and the exonic SNPs used for phase prediction to common SNPs with MAF ≥ 5%. By this criterion, the number of candidate eQTLs per gene varied from 7 to 15,536, with a median of 911, and the number of exonic SNPs per gene varied from 1 to 14,314, with a median of 53. As in the second simulation study, we pre-pruned the SNPs, which resulted in median numbers of 373 (ranging from 1 to 6,898) and 21 (ranging from 1 to 6,282) for candidate eQTLs and exonic SNPs, respectively. The TReC model was applied to all the 19,048 genes, including as covariates the log-transformed total read count per sample and three principal components calculated from the standardized TReC data. For numerical stability, we ran the TReCASE model for a candidate eQTL only if at least five samples who are heterozygous at the candidate eQTL had five or more allele-specific reads.
Thus, the TReCASE model was applied to 14,414 genes.
First, the genome-wide gene-SNP pairs were scanned and the minimum-p SNPs were obtained. can be used to compare the power of different methods for identifying eQTLs. It can be seen that the MLE method was uniformly more powerful than IMP at any cutoff. The relatively small power gain was expected because, for most minimum-p SNPs, the phases were predicted sufficiently well ( Figure 6[a] ). In particular, 53.3% and 48.0% of minimum-p SNPs by MLE and IMP, respectively, had Rsq ≥ 0.7. Due to the prevalence of eQTLs in the human genome, we do not expect the permutation p-values to follow a uniform distribution; the skewness of the histograms in Supplementary Figure S6 seems reasonable.
Next, we identified a total of 2,486 eQTLs by controlling for an FDR of 5%, and determined their cis or trans mechanisms using the cis-trans test at a nominal significance level of 0.01.
Here, we chose a relatively stringent nominal significance level because we wish the test to be less sensitive to the difference between β A and β T , which should always exist in real data even for cis-eQTLs. As shown in Table 3 , there were 141 genes that were identified with eQTLs by the TReC model but lack of the ASE data; as a result, the TReCASE model did not apply to these genes and the eQTLs were undetermined for the mechanism. There are 23 eQTLs that were identified only by TReC; they are expected to be trans-eQTLs. The reason that 7 of them were determined to be cis is that the cis-trans test may lack power. There are 1,876 eQTLs that were identified only by TReCASE; they are expected to be cis-eQTLs. The reason that 195 of them were determined to be trans is due to the difference between β T and β A in the real data. The dominant number of eQTLs that were identified only by TReCASE highlights the importance of exploiting the ASE data for cis-eQTL mapping. Furthermore, there were 410 genes identified with eQTLs by both models. In particular, the two models identified overlapping cis-eQTLs for 179 genes, different cis-eQTLs for 154 genes, and one cis-eQTL and one trans-eQTL for 36 genes. A full list of the 2,486 eQTLs can be found in Supplementary Dataset S1.
At last, we compared the 2,486 eQTLs with the 134 SNPs found to be associated with breast cancer (referred to as trait-associated SNPs [TASs] ) and downloaded from the NHLBI GWAS Catalog . One eQTL, rs4784227 with alleles C and T, was a TAS. The SNP was reported by Long et al. (2010) to have a highly significant association with breast cancer risk, with an odds ratio of 1.19 per T allele in European Americans. Our analysis identified the SNP to be a cis-eQTL for gene TOX3, with the effect of allele T consistently estimated to be −0.77 by either the ASE, TReC or TReCASE model. Since it has been established that TOX3 functions as a tumor suppressor in breast cancer cells (Cowper-Sal et al. 2012) , our eQTL analysis suggested a putative functional role of rs4784227 on breast cancer risk, which has been confirmed in vivo in a breast cancer cell line (Cowper-Sal et al. 2012) . Specifically, rs4784227 is located at a binding motif of the transcription factor FOXA1 and allele T of rs4784227 increases the binding affinity of FOXA1, which in turn represses the expression of TOX3. This cis-eQTL would also be identified using the TReCASE model with IMP, but not using the TReC model alone. In total, 6 eQTLs are in the vicinity (i.e., within 10 kb) of breast cancer TASs (Supplementary Tables S5-S6 ), whereas only 3 are expected by chance, showing evidence of eQTL enrichment among TASs. Like rs4784227, these eQTLs also hold the potential to elucidate the functional roles of the nearby TASs.
DISCUSSION
In summary, we developed a powerful and timely tool for cis-eQTL mapping with RNAseq data. We showed that the proposed approach is more powerful than the existing twostage approach and the use of total gene expression alone. All the proposed methods are implemented in the R package XXX, which is publicly available at our website. With the empirical data from the TCGA, we demonstrated the ability of our approach to discover cis-eQTLs and to elucidate the functional roles of nearby TASs, and the computational efficiency (e.g., only one day on 50 IBM HS22 machines to analyze the TCGA data) of our software to perform a genome-wide analysis. As functional genomics is rapidly progressing towards unraveling the cis-regulatory control of gene expression and many large-scale RNA-seq studies are underway, our analytical tool may play a key part in the coming years.
Our work significantly improves over the one by Sun (2012) . First, we do not phase the candidate eQTL as a priori. Our maximum-likelihood methods phase the candidate eQTL and assess the cis-effect in an iterative fashion, and thus can remove the bias in the estimated effect size and boost the power in detecting a cis-eQTL. Second, we base our methods on score statistics and devise a permutation process that is tailored to the score statistics, thereby reducing the computation time to a mere ∼5% of the time required the traditional permutation process. Third, for each SNP-gene pair, Sun (2012) adopted a strategy of first deciding on the cis or trans mechanism by the cis-trans test and then choosing the TReC or TReCASE model based on the test result. This strategy would incur a great computation cost because the computationally intensive cis-trans test has to be applied for every possible SNP-gene pair. In addition, it is unnatural to distinguish between the cis and trans mechanisms before any association is detected.
For the two-stage approach, we have used a small number of exonic SNPs to predict the phase of the candidate eQTL, so that the two-stage approach is compared with our maximumlikelihood approach on equal footing. An alternative is to use a hidden-Markov model (HMM) (Stephens et al. 2001; Browning and Browning 2009; Li et al. 2010; Delaneau et al. 2012) , which exploits the LD information over a larger region, and thus may yield more accurate prediction of phase in certain situations. The conclusions regarding the relative merits of the maximum-likelihood approach versus the two-stage approach are expected to hold when an HMM is used.
We have assumed independence between the covariates X and the diplotype H, so that the probability Pr(X|H) factored out from the likelihood (2). This assumption is reasonable if the covariates include demographic variables, such as age and gender, and environmental exposures. If it is believed that X and H are correlated, then we can extend the methodology by adopting a generalized odds-ratio function for Pr(X|H) (Hu et al. 2010) . Likelihoods (2) and (6) will then involve the (potentially infinite-dimensional) distribution function of X, which will greatly increase the theoretical and numerical complexity. In addition, assessing the significance of the minimum-p SNP should then rely on the parametric bootstrap, instead of permutation.
We have focused on the minimum-p SNP for each gene. It is possible that other SNPs act independently on the gene expression, but to a lesser extent. To detect such SNPs, we can include the minimum-p SNP as a covariate and search for additional eQTLs conditional on the most significant one. Although it is straightforward to do so with the TReC model, it is less transparent with the ASE model. Not only the regression model (1) should include the minimum-p SNP as a covariate, but also the likelihood (2) should account for the phasing uncertainties of both SNPs.
APPENDIX A: Rsq Measure of Phasing Accuracy
The development of Rsq follows the rational of Li et al. (2010) in developing a measure of accuracy for imputed SNP genotypes. First, for a candidate eQTL and M exonic SNPs, we estimate the corresponding π by maximizing the likelihood that uses the genotype data only:
Due to the missing H i , the expectation-maximization (EM) algorithm is the method of choice for the maximization. In the E-step, we evaluate
, and in the M-step, we update
ω ikl , where I(.) is the indicator function, i = 1, . . . , N , and k, l, k * , l * = 1, . . . , K. Denote the maximum likelihood estimator (MLE) of π by π. Then, for an individual with G = 1 and H = ( h m , h n ), we can estimate G 1 by the expected number of allele 1 on the same chromosome as h m , i.e.,
where the subscript (1, m) represents the haplotype consisting of allele 1 at the candidate eQTL and h m at the exonic SNPs. Although G 1 is not a form of phasing due to the continuous nature, it is an unbiased estimator of G 1 . To quantify the phasing accuracy, a natural measure would be the Pearson correlation coefficient r 2 between G 1 and the underlying G 1 . Since G 1 is unknown, we estimate r 2 by the ratio of the sample variance of G 1 with what would be expected if G 1 was observed (Li et al. 2010) , and refer to the estimated r 2 as the Rsq measure. Specifically, In summary, we develop a measure of phasing accuracy to be
We note that the calculation of Rsq, though involving an iterative process to solve for π, is computationally fast and scalable to the genome-wide scan.
APPENDIX B: Maximum Likelihood Inference
B.1 Inference for ASE model
We obtain the MLEs of β A , ψ, and π based on the likelihood (2) via the following EM algorithm. The complete-data log-likelihood is
In the E-step, we evaluate
, which can be shown to be
In the M-step, we maximize l A (β A , ψ, π) with
we update π k , k = 1, . . . , K, by
and update β A and ψ by a one-step Newton-Raphson iteration. Starting with β A = 0, ψ = 0 and π = π, where π is the MLE based on the likelihood (S1), we iterate between the E-step and M-step until the change in the observed-data log-likelihood is negligible. Denote the MLEs of β A , ψ, and π by β A , ψ, and π.
We can estimate the standard errors of β A , ψ, and π by the Louis formula (Louis 1982).
, where p k,l was defined in expression (1). For i = 1, . . . , N and k, l = 1, . . . , K, calculate the vectoṙ
Calculate the block diagonal matrixl ikl with two blocks. The first block is a 2×2 matrix with two diagonal elements,
and
and an off-diagonal element
The second block is a (K − 1)
matrix with all elements being 1. For subjects with R i = 0, the elements inl ikl andl ikl associated with the derivative with respect to β A or ψ are zero. The covariance matrix for (
A , where
and ν denotes the transpose of the vector ν. Note that ω ikl ,l ikl andl ikl should be evaluated at the MLEs. The standard errors for β A , ψ, and π 1 , . . . , π K−1 are the square-roots of the diagonal elements in Σ A . The standard error for π K = 1 − K−1 k=1 π k is the square root of (1, . . . , 1)B(1, . . . , 1) , where B is the last (K − 1) × (K − 1) sub-matrix of Σ A .
To calculate the score statistic for testing H 0 : β A = 0, we first produce the restricted MLE of the nuisance parameter δ = (ψ, π 1 , . . . , π K−1 ) , denoted by δ = ( ψ, π 1 , . . . , π K−1 ) .
The π 1 , . . . , π K−1 turn out to be the MLEs based on the likelihood (7), and ψ maximizes
Then, the score and information functions for (β A , δ ) , which take the forms U A = ikl ω ikllikl and I A , respectively, are evaluated at (0, δ ) . Based on the partition
where β represents β A , the score statistic n −1/2 U A,β is asymptotically zero-mean normal with a variance that can be consistently estimated by n −1 I A,ββ − I A,βδ I −1
A,δδ I A,δβ .
B.2 Inference for TReC model
The MLEs of β T , γ, and φ, denoted by β T , γ, and φ, based on the likelihood (5) can be obtained via the Newton-Raphson algorithm with the first and negative second derivative of
is given by I −1
T , which is evaluated at the MLEs.
To calculate the score statistic for testing H 0 : β T = 0, we first produce the restricted MLEs of the nuisance parameter ξ = (γ, φ) , denoted by ξ = ( γ, φ) . Then, the score and information functions for (β T , ξ ) , which take the forms U T and I T , respectively, are evaluated at (0, ξ ) . Based on the partition
where β represents β T , the score statistic n −1/2 U T,β is asymptotically zero-mean normal with a variance that can be consistently estimated by n
T,ξξ I T,ξβ .
B.3 Inference for TReCASE model
Let β = β A = β T . The MLEs of β, δ, and ξ based on the likelihood (6) can be obtained via a similar EM algorithm as for the ASE model. The complete-data log-likelihood is l TA (β, δ, ξ) =
In the E-step, we evaluate the ω ikl in (8). In the M-step, we update π k ,
in (9) and update β, ψ, and ξ by a one-step Newton-Raphson iteration. Denote the MLEs of β, δ, and ξ by β, δ, and ξ. According to their definitions, δ = ( ψ, π 1 , . . . , π K−1 ) and ξ = ( γ, φ) , as they are MLEs for different models. The covariance
TA , where
To calculate the score statistic for testing H 0 : β = 0, we first obtain the restricted MLEs for the nuisance parameter τ = (δ , ξ ) to be τ = ( δ , ξ ) , where δ and ξ are restricted MLEs from the ASE and TReC models, respectively. Then, the score and information functions for (β, τ ) , which take the forms U TA = (U A,β + U T,β , U A,δ , U T,ξ ) and I TA , respectively, are evaluated at (0, τ ) . The score statistic and the variance estimator can be constructed in the same fashion as for the ASE model.
B.4 Cis-trans test
Let β A = β and β T = β + α. To calculate the score statistic for testing H 0 : α = 0, we first obtain the restricted MLEs for the nuisance parameter τ
where β, δ and ξ are the MLEs of β, δ, and ξ, respectively, from the TReCASE model. The score and information functions for (α, (τ * ) ) take the forms
respectively, which are evaluated at (0, ( τ * ) ) . The score statistic and the variance estimator can be constructed in the same fashion as for the ASE model. 
SUPPLEMENTARY METHODS
S1. Validity of the Two-Stage Method
We focus on the ASE model, the result of which can be readily extended to the TReCASE model. The two-stage method first phases the genotype of the candidate eQTL, i.e., inferring the unknown value of H i by H i for the ith individual. The phasing is performed by any of the commonly used algorithms without considering the information of gene expression. Then, the cis-eQTL mapping proceeds by treating H i as observed. The standard likelihood tests, e.g., the Wald, likelihood-ratio, and score tests, for H 0 : β A = 0 based on the "likelihood"
has the following property. Provided that H is independent of R 1 given R, which generally holds as long as there is no differential mapping error, the standard likelihood tests yield correct type I error.
The two-stage method is analogous to the genotype imputation method proposed by Hu and Lin (2010) in the context of untyped SNPs. The arguments of Hu and Lin to prove the validity of their imputation method can be used to prove the validity of the two-stage method with a minor modification. Specifically, the former conditioned on the external reference panel, whereas the latter should condition on the genetic data (G i , H i )(i = 1, . . . , N ).
S2. Additional Details of the TCGA Data Analysis
We obtained the bam files of RNA-seq data from the Cancer Genomics Hub. These files contain 50+50bp paired-end reads, which have been mapped and undergone quality control (QC) procedures of the TCGA group. We applied a few extra QC steps that were implemented in the function prepareBAM of the R package asSeq. Specifically, we removed a read if it satisfied one of the following criteria: (1) the average sequencing quality score across all base pairs of the read is ≤ 10; (2) the mapping quality score is ≤ 10; and (3) the read is not uniquely mapped. Note that (1)-(3) were applied to each end of a read. On average, ∼80% of reads per sample survived this round of QC ( Figure S7[a] ).
We derived the TReC from the RNA-seq data using the function countReads in the R package isoform (http://www.bios.unc.edu/∼weisun/software/isoform.htm). A read with two ends passing QC should not be counted twice, because the two ends are dependent.
To quantify the ASE, we first extracted the allele-specific reads of a sample into two separate bam files corresponding to the two haplotypes, using extractAsReads in asSeq. A read is allele-specific if at least one of the two ends overlaps with at least one SNP at which the sample carries a heterozygous genotype. Then, we derived the ASE using countReads again.
As shown in Figure S7 [b], the total number of allele-specific reads per sample is about 3.4% of the total number of reads that were mapped to the exonic regions.
For eQTL mapping using the TReC model, we should account for both the observed and the unobserved non-genetic factors that may influence the gene expression. One obvious factor is the read-depth variation across samples. Other factors include batch effects and demographical characteristics such as age. Due to the limited sample size, we used a few principal components (PCs) derived from the TReC data as the surrogates of batch effects.
Clinical relevant variables, such as the tumor stage, ER status, and breast cancer subtypes, may also influence the gene expression. However, we chose not to include them because they tend to diminish the biologically relevant signals in the gene expression. Figure S1 . Power of the ASE model for testing a cis-eQTL in the first simulation study. The nominal significance level is 0.05. MLE, IMP, and TRUE are the maximum-likelihood method, the two-stage method, and the method using the true phase, respectively. Each power estimate is based on 10,000 replicates.
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− log 10 (permutation p−value) Figure S2 . Quantile-quantile plots of − log 10 (permutation p-values) in the second simulation study. The cis-effect size is zero. The red lines represent the theoretical null distribution, i.e., the uniform distribution. The left and right panels pertain to the TReC and TReCASE models with the MLE method, respectively. Each plot is based on 5,000 replicates. Figure S4 . Power of the cis-trans test for detecting a trans-effect in the third simulation study. We set β A = 0, which is implied by a trans-effect. MLE, IMP, and TRUE are the maximum-likelihood method, the two-stage method, and the method using the true phase, respectively. The nominal significance level is 0.05. Each power estimate is based on 10,000 replicates. Figure S5 . Power of the cis-trans test conditional on β A = 0.5 in the third simulation study. When β T = β A = 0.5, which corresponds to the null hypothesis, the "power" is the type I error. MLE, IMP, and TRUE are the maximum-likelihood method, the two-stage method, and the method using the true phase, respectively. The nominal significance level is 0.05. Each power estimate is based on 10,000 replicates. . Expected numbers were obtained by randomly sampling 2,509 SNPs among all the candidate eQTLs, one per gene, and assessing their distance with the 134 TASs. The process was repeated 100 times.
